A pharmaceutical composition comprising: (a) a water-insoluble antipsychotic agent, wherein the water-insoluble antipsychotic agent is aripiprazole, a compound of formula I, or a compound of formula II, or pharmaceutically acceptable salts, hydrates, or solvates thereof: wherein R a is absent, and R b is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; or R b is absent, and R a is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; R c is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; wherein each R 1 is independently selected from the group consisting of hydrogen, substituted or unsubstituted aliphatic, and substituted or unsubstituted aryl; and wherein each R 2 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; wherein the substituted aliphatic, aryl, or heteroaryl are substituted with one or more substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic; wherein Y ⊖ is a pharmaceutically acceptable counterion; and wherein ------------ represents a single or double bond; (b) a C 1-6 alkyl ester of a C 10-20 fatty acid, wherein the alkyl ester of a fatty acid is ethyl oleate or isopropyl myristate; (c) a polyoxy ethylene derivative of a sorbitan ester of a carboxylic acid, wherein the carboxylic acid comprises 8-20 carbon atoms; and (d) an aqueous vehicle; wherein the composition forms an aqueous, flocculated, injectable suspension. (a) a water-insoluble antipsychotic agent, wherein the water-insoluble antipsychotic agent is aripiprazole, a compound of formula I, or a compound of formula II, or pharmaceutically acceptable salts, hydrates, or solvates thereof: wherein R a is absent, and R b is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; or R b is absent, and R a is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; R c is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; wherein each R 1 is independently selected from the group consisting of hydrogen, substituted or unsubstituted aliphatic, and substituted or unsubstituted aryl; and wherein each R 2 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; wherein the substituted aliphatic, aryl, or heteroaryl are substituted with one or more substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic; wherein Y ⊖ is a pharmaceutically acceptable counterion; and wherein ------------ represents a single or double bond; R a is absent, and R b is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; or R b is absent, and R a is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; R c is -CH 2 OC R 1, -CH 2 OC OR 1, -CH 2 OC N(R 1) 2 or -C R 1; wherein each R 1 is independently selected from the group consisting of hydrogen, substituted or unsubstituted aliphatic, and substituted or unsubstituted aryl; and wherein each R 2 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; wherein the substituted aliphatic, aryl, or heteroaryl are substituted with one or more substituents selected from the group consisting of halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic; wherein Y ⊖ is a pharmaceutically acceptable counterion; and wherein ------------ represents a single or double bond; (b) a C 1-6 alkyl ester of a C 10-20 fatty acid, wherein the alkyl ester of a fatty acid is ethyl oleate or isopropyl myristate; (c) a polyoxy ethylene derivative of a sorbitan ester of a carboxylic acid, wherein the carboxylic acid comprises 8-20 carbon atoms; and (d) an aqueous vehicle;